GSWM
LXRX icon

Golden State Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Golden State Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,700
Closed -$4.25K – 1683
2025
Q4 		$4.25K Hold
3,700
– – ﹤0.01% 1268
2025
Q3 		$5K Hold
3,700
– – ﹤0.01% 1253
2025
Q2 		$3.5K Hold
3,700
– – ﹤0.01% 1290
2025
Q1 		$1.71K Buy
+3,700
New +$2.33K ﹤0.01% 1343

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Golden State Wealth Management's LXRX Position: Q1 2026 in Review

Golden State Wealth Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2026, closing a stake of 3,700 shares — an estimated $4.25K sold.

Golden State Wealth Management first reported a position in LXRX in Q1 2025 and held it in 4 quarters. The position peaked at $5K in Q3 2025. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Golden State Wealth Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Golden State Wealth Management sold 3,700 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $4.25K.
  • Golden State Wealth Management first reported a position in Lexicon Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Golden State Wealth Management's Lexicon Pharmaceuticals position peaked at $5K in Q3 2025.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Golden State Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.